Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Mika Lin"'
Autor:
Atsuko Ogino, Jihyun Choi, Mika Lin, Margaret K. Wilkens, Antonio Calles, Man Xu, Anika E. Adeni, Emily S. Chambers, Marzia Capelletti, Mohit Butaney, Nathanael S. Gray, Prafulla C. Gokhale, Sangeetha Palakurthi, Paul Kirschmeier, Geoffrey R. Oxnard, Lynette M. Sholl, Pasi A. Jänne
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 27-42 (2021)
Small‐cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next‐generation sequencing (NGS) and by characterizing a representative patient‐derived model. We performed ta
Externí odkaz:
https://doaj.org/article/16f2e5591dc747019078af19041d15e0
Autor:
Chiara Ambrogio, Pasi A. Jänne, Mark M. Awad, Prafulla C. Gokhale, David Santamaria, Marie-Julie Nokin, Elodie Richard, Yunhan Chen, Kshiti H. Dholakia, Jens Köhler, Amanda J. Redig, Chhayheng Chhoeu, Joao Victor Alessi, Yue Xu, Jiaqi Li, Heidi M. Haikala, Mika Lin, Haiyun Wang, Raymond Paranal, Xinan Wang, Yoonji Eum, Enrico Patrucco, Alessia Mira, Jeffrey J. Okoro, Jieun Son, Biagio Ricciuti
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e908ecdb4bf36d5ab7cc98336d10d7d
https://doi.org/10.1158/1078-0432.22484111.v1
https://doi.org/10.1158/1078-0432.22484111.v1
Autor:
Pasi A. Jänne, Nathanael S. Gray, Michael J. Eck, Michael D. Cameron, Prafulla C. Gokhale, Man Xu, Stephen Wang, Michael J. Poitras, Pinar Ö. Eser, Nicholas P. Kwiatkowski, John M. Hatcher, Mika Lin, Alyssa Verano, Heidi M. Haikala, Yoonji Eum, Tyler S. Beyett, Jaebong Jang, Jieun Son
Supplementary Data from A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa51d44206e743a06a491f4c4226891
https://doi.org/10.1158/0008-5472.22431270
https://doi.org/10.1158/0008-5472.22431270
Autor:
Geoffrey R. Oxnard, Alexander Drilon, S. Michael Rothenberg, Pasi A. Jänne, Marc Ladanyi, Barry S. Taylor, Lynette M. Sholl, Bob T. Li, Jaclyn F. Hechtman, Kevin Ebata, Morana Vojnic, Jenna E. Scanlon, Elizabeth A. Olek, Binoj C. Nair, Marina S.D. Milan, Mika Lin, Elaine M. Kelley, Dahlia N. Henry, Elena V. Ivanova, Eric Gladstone, Monika A. Davare, Arrien A. Bertram, Jieun Son, Jennifer F. Kherani, Romel Somwar, Sarah E. Clifford, Melissa L. Johnson, Ezra Y. Rosen
Purpose:The RET proto-oncogene encodes a receptor tyrosine kinase that is activated by gene fusion in 1%–2% of non–small cell lung cancers (NSCLC) and rarely in other cancer types. Selpercatinib is a highly selective RET kinase inhibitor that has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9461667101ab35b16334a2658cac6e69
https://doi.org/10.1158/1078-0432.c.6529967.v1
https://doi.org/10.1158/1078-0432.c.6529967.v1
Autor:
Geoffrey R. Oxnard, Alexander Drilon, S. Michael Rothenberg, Pasi A. Jänne, Marc Ladanyi, Barry S. Taylor, Lynette M. Sholl, Bob T. Li, Jaclyn F. Hechtman, Kevin Ebata, Morana Vojnic, Jenna E. Scanlon, Elizabeth A. Olek, Binoj C. Nair, Marina S.D. Milan, Mika Lin, Elaine M. Kelley, Dahlia N. Henry, Elena V. Ivanova, Eric Gladstone, Monika A. Davare, Arrien A. Bertram, Jieun Son, Jennifer F. Kherani, Romel Somwar, Sarah E. Clifford, Melissa L. Johnson, Ezra Y. Rosen
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3222331f9df0def6140f62b8dd62ce6d
https://doi.org/10.1158/1078-0432.22478522.v1
https://doi.org/10.1158/1078-0432.22478522.v1
Autor:
Geoffrey R. Oxnard, Alexander Drilon, S. Michael Rothenberg, Pasi A. Jänne, Marc Ladanyi, Barry S. Taylor, Lynette M. Sholl, Bob T. Li, Jaclyn F. Hechtman, Kevin Ebata, Morana Vojnic, Jenna E. Scanlon, Elizabeth A. Olek, Binoj C. Nair, Marina S.D. Milan, Mika Lin, Elaine M. Kelley, Dahlia N. Henry, Elena V. Ivanova, Eric Gladstone, Monika A. Davare, Arrien A. Bertram, Jieun Son, Jennifer F. Kherani, Romel Somwar, Sarah E. Clifford, Melissa L. Johnson, Ezra Y. Rosen
Supplemental Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2689208102f49f2ea96c9757e087b52b
https://doi.org/10.1158/1078-0432.22478525
https://doi.org/10.1158/1078-0432.22478525
Autor:
Pasi A. Jänne, Nathanael S. Gray, Michael J. Eck, Michael D. Cameron, Prafulla C. Gokhale, Man Xu, Stephen Wang, Michael J. Poitras, Pinar Ö. Eser, Nicholas P. Kwiatkowski, John M. Hatcher, Mika Lin, Alyssa Verano, Heidi M. Haikala, Yoonji Eum, Tyler S. Beyett, Jaebong Jang, Jieun Son
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97a8ef884fce9cee6f7c5310978d793e
https://doi.org/10.1158/0008-5472.c.6513855.v1
https://doi.org/10.1158/0008-5472.c.6513855.v1
Autor:
Jieun Son, Jaebong Jang, Tyler S. Beyett, Yoonji Eum, Heidi M. Haikala, Alyssa Verano, Mika Lin, John M. Hatcher, Nicholas P. Kwiatkowski, Pinar Ö. Eser, Michael J. Poitras, Stephen Wang, Man Xu, Prafulla C. Gokhale, Michael D. Cameron, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
Publikováno v:
Cancer Research. 82:1633-1645
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd25edc86a54a2b4204011c49a45ac0
https://doi.org/10.1158/0008-5472.can-21-2693
https://doi.org/10.1158/0008-5472.can-21-2693
Autor:
Margaret K. Wilkens, Monica Musteanu, Aine Knott, Magda Bahcall, Shripad V. Bhagwat, Kara M. Soroko, Prafulla C. Gokhale, Jens Köhler, Emily S. Chambers, Mika Lin, Yutong Zhao, Hong L. Tiv, Jihyun Choi, Jason Manro, Ramon V. Tiu, Arrien A. Bertram, Pasi A. Jänne, Atsuko Ogino, Cloud P. Paweletz, Jiaqi Li, Chiara Ambrogio
Publikováno v:
Molecular Cancer Therapeutics. 20:641-654
RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB pathways. Within the MAPK pathway, ERK1/2 proteins exert a bottleneck function for transm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b52a75d6e0156073726473d7d901c2
https://doi.org/10.1158/1535-7163.mct-20-0531
https://doi.org/10.1158/1535-7163.mct-20-0531
Autor:
Marc Ladanyi, Bob T. Li, Jennifer Kherani, Elena Ivanova, Arrien A. Bertram, Ezra Y. Rosen, Elaine M. Kelley, Jieun Son, Marina S.D. Milan, Jaclyn F. Hechtman, Romel Somwar, Kevin Ebata, Alexander Drilon, Melissa Lynne Johnson, Sarah E. Clifford, Jenna E. Scanlon, Barry S. Taylor, Geoffrey R. Oxnard, Eric Gladstone, S Michael Rothenberg, Elizabeth Olek, Monika A. Davare, Binoj Nair, Pasi A. Jänne, Mika Lin, Lynette M. Sholl, Morana Vojnic, Dahlia Henry
Publikováno v:
Clin Cancer Res
Purpose: The RET proto-oncogene encodes a receptor tyrosine kinase that is activated by gene fusion in 1%–2% of non–small cell lung cancers (NSCLC) and rarely in other cancer types. Selpercatinib is a highly selective RET kinase inhibitor that ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3eedfba373fe8e1440677846f5c39b
https://doi.org/10.1158/1078-0432.ccr-20-2278
https://doi.org/10.1158/1078-0432.ccr-20-2278